Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study for the Treatment of Painful Diabetic Neuropathy

Phase 3

Completed

Conditions: Diabetic Neuropathy, Painful

First Posted Date: 2003-04-16

Last Posted Date: 2007-05-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 660

Registration Number: NCT00058968

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLilly (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pembroke Pines, Florida, United States

Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer

Phase 2

Terminated

Conditions: Ovarian Cancer
Peritoneal Cancer

First Posted Date: 2003-03-04

Last Posted Date: 2006-09-15

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT00055432

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Atlanta, Georgia, United States

A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Neoplasms

Interventions: Biological: Cetuximab

First Posted Date: 2003-03-04

Last Posted Date: 2010-04-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 744

Registration Number: NCT00055419

Locations: 🇺🇸
ImClone Investigational Site, Green Bay, Wisconsin, United States

A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2003-02-24

Last Posted Date: 2007-01-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 130

Registration Number: NCT00055250

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5pm Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Lakeland, Florida, United States

Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

First Posted Date: 2003-01-20

Last Posted Date: 2006-07-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 200

Registration Number: NCT00051909

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: Alendronate Sodium
Drug: Teriparatide
Drug: Placebo

First Posted Date: 2003-01-14

Last Posted Date: 2009-03-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 428

Registration Number: NCT00051558

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ponce, Puerto Rico

ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.

Phase 2

Completed

Conditions: Lung Neoplasms

First Posted Date: 2003-01-14

Last Posted Date: 2006-07-20

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT00051506

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Charleston, South Carolina, United States

ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2003-01-14

Last Posted Date: 2006-07-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 50

Registration Number: NCT00051493

Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

First Posted Date: 2003-01-09

Last Posted Date: 2007-06-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 107

Registration Number: NCT00051298

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician., Moscow, Russian Federation
🇺🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician, Cerritos, California, United States

Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying

Phase 2

Completed

Conditions: Gastroparesis

Interventions: Drug: placebo
Drug: tadalafil

First Posted Date: 2002-12-18

Last Posted Date: 2007-11-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 2

Registration Number: NCT00050609

Locations: 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saskatoon, Saskatchewan, Canada

Home Terms & Conditions Privacy Policy